{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:17:01Z","timestamp":1760059021592,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Cardiac amyloidosis (CA), an infiltrative restrictive cardiomyopathy, is a frequently underrecognized etiology of diastolic heart failure (HF). This study aimed to evaluate inpatient outcomes among patients hospitalized with decompensated diastolic HF with and without a secondary diagnosis of amyloidosis, utilizing data from the National Inpatient Sample (2018\u20132021). Among 2,444,699 patients hospitalized for decompensated diastolic HF, 9205 (0.3%) had a documented secondary diagnosis of amyloidosis. After 1:1 propensity-score matching, 1841 patients in each group were analyzed. Multivariate logistic regression revealed that the presence of amyloidosis was associated with significantly higher odds of in-hospital mortality (4.0% vs. 2.7%), cardiogenic shock (5.4% vs. 2.4%), acute kidney injury (28.3% vs. 22.0%), ventricular tachycardia (12.4% vs. 6.0%), and acute myocardial injury (9.5% vs. 6.0%) (all p &lt; 0.05). Additionally, patients with amyloidosis had a longer mean length of stay (7.1 vs. 5.7 days) and higher mean hospitalization costs ($85,594 vs. $48,484, p &lt; 0.05). Although the overall incidence of acute myocardial injury was elevated, subgroup analysis of ST-elevation and non\u2013ST-elevation myocardial infarction revealed no significant differences. These findings underscore the considerable clinical and economic burden of amyloidosis in patients hospitalized with decompensated diastolic heart failure.<\/jats:p>","DOI":"10.3390\/jcdd12050190","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:37:13Z","timestamp":1747633033000},"page":"190","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Insights on Inpatient Outcomes in Diastolic Heart Failure with and Without Amyloidosis: A Nationwide Propensity-Matched Analysis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7689-3750","authenticated-orcid":false,"given":"Aravind","family":"Dilli Babu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirza Faris","family":"Ali Baig","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Asante Three Rivers Medical Center, Grants Pass, OR 97527, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7754-9953","authenticated-orcid":false,"given":"David A.","family":"Baran","sequence":"additional","affiliation":[{"name":"Advanced Heart Failure and Transplantation Section of Heart Failure & Cardiac Transplant Medicine, Cleveland Clinic, Weston, FL 33331, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Estep","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cleveland Clinic, Weston, FL 33331, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wolinsky","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cleveland Clinic, Weston, FL 33331, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina Thakkar","family":"Rivera","sequence":"additional","affiliation":[{"name":"Advanced Heart Failure and Transplantation Section of Heart Failure & Cardiac Transplant Medicine, Cleveland Clinic, Weston, FL 33331, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram","family":"Bhutani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshit","family":"Narula","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Chaulagain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Snipelisky","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Robles","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.hlc.2022.08.002","article-title":"Prevalence and Risk Factors of Cardiac Amyloidosis in Heart Failure: A Systematic Review and Meta-Analysis","volume":"31","author":"See","year":"2022","journal-title":"Hear. Lung Circ."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.acvd.2018.03.004","article-title":"Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure","volume":"111","author":"Fard","year":"2018","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_8","unstructured":"HCUP National Inpatient Sample (NIS) (2024, June 10). Healthcare Cost and Utilization Project (HCUP). 2012. Agency for Healthcare Research and Quality, Rockville, MD. HCUP-US NIS Overview. Hcup-Usahrqgov, Available online: https:\/\/hcup-us.ahrq.gov\/nisoverview.jsp."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jaccao.2020.10.007","article-title":"Amyloidosis and 30-Day Outcomes Among Patients with Heart Failure: A Nationwide Readmissions Database Study","volume":"2","author":"Arora","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e005407","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of Cardiac Amyloidosis\u2013Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ. Hear. Fail."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/13506129.2019.1618261","article-title":"Trends and causes of hospitalizations in patients with amyloidosis","volume":"26","author":"Patil","year":"2019","journal-title":"Amyloid"},{"key":"ref_12","unstructured":"Stata 18 Software (2024, June 10). Stata|FAQ: Citing Stata Software, Documentation, and FAQs. Statacom., Available online: https:\/\/www.stata.com\/support\/faqs\/resources\/citing-software-documentation-faqs\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/03007995.2021.1913109","article-title":"Incidence rate of hospitalization and mortality in the first year following initial diagnosis of cardiac amyloidosis in the US claims databases","volume":"37","author":"Wang","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.amjcard.2023.07.023","article-title":"Adverse Outcomes in Hospitalizations for Amyloid-Related Heart Failure","volume":"203","author":"Appunni","year":"2023","journal-title":"Am. J. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Monte, I.P., Faro, D.C., Trimarchi, G., de Gaetano, F., Campisi, M., Losi, V., Teresi, L., Di Bella, G., Tamburino, C., and de Gregorio, C. (2023). Left Atrial Strain Imaging by Speckle Tracking Echocardiography: The Supportive Diagnostic Value in Cardiac Amyloidosis and Hypertrophic Cardiomyopathy. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10060261"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.amjcard.2023.09.055","article-title":"Myocardial Work Appraisal in Transthyretin Cardiac Amyloidosis and Nonobstructive Hypertrophic Cardiomyopathy","volume":"208","author":"Trimarchi","year":"2023","journal-title":"Am. J. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ramsell, S., Bermudez, C.A., Baiyee, C.A.M.T., Rodgers, B., Parikh, S., Almaani, S., Sharma, N., LoRusso, S., Freimer, M., and Redder, E. (2022). Beta-Adrenergic Antagonist Tolerance in Amyloid Cardiomyopathy. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.907597"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCRESAHA.117.310643","article-title":"Amyloid Cardiomyopathy","volume":"120","author":"Liao","year":"2017","journal-title":"Circ. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.amjcard.2019.08.045","article-title":"Increasing Rate of Hospital Admissions in Patients with Amyloidosis (from the National Inpatient Sample)","volume":"124","author":"Sperry","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e220185","DOI":"10.2217\/cer-2022-0185","article-title":"In-hospital mortality in amyloid light chain amyloidosis: Analysis of the Premier Healthcare Database","volume":"12","author":"Quock","year":"2023","journal-title":"J. Comp. Eff. Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Feitosa, V.A., Neves, P.D.M.M., Jorge, L.B., Noronha, I.L., and Onuchic, L.F. (2022). Renal amyloidosis: A new time for a complete diagnosis. Braz. J. Med. Biol. Res. Rev. Bras. Pesqui. Medicas E Biol., 55.","DOI":"10.1590\/1414-431x2022e12284"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/jce.14541","article-title":"Effect of ICD implantation on cardiovascular outcomes in patients with cardiac amyloidosis: A systematic review and meta-anaylsis","volume":"31","author":"Halawa","year":"2020","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of Arrhythmias in Cardiac Amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/CIRCULATIONAHA.120.052136","article-title":"Prevalence of Atrial Fibrillation and Thromboembolic Risk in Wild-Type Transthyretin Amyloid Cardiomyopathy","volume":"143","author":"Bukhari","year":"2021","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: Clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: Prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e003002","DOI":"10.1136\/openhrt-2024-003002","article-title":"Optimal timing of oral anticoagulation initiation in patients with acute ischaemic stroke and atrial fibrillation: A comprehensive meta-analysis and systematic review","volume":"11","author":"Singh","year":"2024","journal-title":"Open Heart."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/pace.14458","article-title":"Ventricular arrhythmia burden and implantable cardioverter-defibrillator outcomes in transthyretin cardiac amyloidosis","volume":"45","author":"Brown","year":"2022","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.hrthm.2019.05.007","article-title":"2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy","volume":"16","author":"Towbin","year":"2019","journal-title":"Heart Rhythm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"Cardiol. Ther."},{"key":"ref_31","first-page":"e002558","article-title":"Transthyretin Cardiac Amyloidosis in Black Americans","volume":"9","author":"Shah","year":"2016","journal-title":"Circ. Hear. Fail."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jchf.2022.06.006","article-title":"Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy with Impaired Left Ventricular Function","volume":"10","author":"Martyn","year":"2022","journal-title":"JACC Hear. Fail."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/12\/5\/190\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:34:13Z","timestamp":1760031253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/12\/5\/190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcdd12050190"],"URL":"https:\/\/doi.org\/10.3390\/jcdd12050190","relation":{},"ISSN":["2308-3425"],"issn-type":[{"type":"electronic","value":"2308-3425"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}